scholarly article | Q13442814 |
P6179 | Dimensions Publication ID | 1034385180 |
P356 | DOI | 10.1038/SREP30939 |
P932 | PMC publication ID | 4971519 |
P698 | PubMed publication ID | 27484655 |
P2093 | author name string | Hong Tang | |
Minkyung Yi | |||
Shuichi Kaneko | |||
Masao Honda | |||
Takayoshi Shirasaki | |||
Tetsuro Shimakami | |||
Fanwei Liu | |||
Kazuhisa Murai | |||
Masaya Funaki | |||
Seishi Murakami | |||
P2860 | cites work | Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010 | Q21534928 |
Structural basis for viral 5'-PPP-RNA recognition by human IFIT proteins | Q24310342 | ||
Regulating intracellular antiviral defense and permissiveness to hepatitis C virus RNA replication through a cellular RNA helicase, RIG-I | Q24556673 | ||
Genetic variation in IL28B and spontaneous clearance of hepatitis C virus | Q24596340 | ||
Regulation of hepatitis C virus translation and infectious virus production by the microRNA miR-122 | Q24609988 | ||
The yin and yang of hepatitis C: synthesis and decay of hepatitis C virus RNA | Q26800446 | ||
Production of infectious genotype 1a hepatitis C virus (Hutchinson strain) in cultured human hepatoma cells | Q27473106 | ||
Structural basis of RNA recognition and activation by innate immune receptor RIG-I | Q27674465 | ||
Global epidemiology of hepatitis C virus infection | Q27860799 | ||
Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA | Q27861124 | ||
Treatment of HCV infection by targeting microRNA | Q29547712 | ||
IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy | Q29614896 | ||
Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection | Q29615959 | ||
LNA-mediated microRNA silencing in non-human primates | Q29615962 | ||
Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C | Q29619541 | ||
Kinetic analyses reveal potent and early blockade of hepatitis C virus assembly by NS5A inhibitors. | Q33934312 | ||
PSI-7851, a pronucleotide of beta-D-2'-deoxy-2'-fluoro-2'-C-methyluridine monophosphate, is a potent and pan-genotype inhibitor of hepatitis C virus replication | Q34045444 | ||
Direct-acting antivirals for the treatment of hepatitis C virus infection: optimizing current IFN-free treatment and future perspectives | Q34045760 | ||
Hepatitis C virus genetics affects miR-122 requirements and response to miR-122 inhibitors. | Q34539024 | ||
MicroRNA-122 antagonism against hepatitis C virus genotypes 1-6 and reduced efficacy by host RNA insertion or mutations in the HCV 5' UTR. | Q34721015 | ||
Position-dependent function for a tandem microRNA miR-122-binding site located in the hepatitis C virus RNA genome | Q34795106 | ||
Protease Inhibitor–Resistant Hepatitis C Virus Mutants With Reduced Fitness From Impaired Production of Infectious Virus | Q35164008 | ||
Adaptive mutations producing efficient replication of genotype 1a hepatitis C virus RNA in normal Huh7 cells | Q35702021 | ||
Stabilization of hepatitis C virus RNA by an Ago2-miR-122 complex. | Q35735135 | ||
Interferon-free antiviral combination therapies without nucleosidic polymerase inhibitors | Q38274463 | ||
La protein is a potent regulator of replication of hepatitis C virus in patients with chronic hepatitis C through internal ribosomal entry site-directed translation | Q38331129 | ||
The importance of resistance to direct antiviral drugs in HCV infection in clinical practice | Q38593397 | ||
Genotype and subtype profiling of PSI-7977 as a nucleotide inhibitor of hepatitis C virus | Q39376758 | ||
Nonhepatic cell lines HeLa and 293 support efficient replication of the hepatitis C virus genotype 2a subgenomic replicon. | Q40481063 | ||
Long term persistence of NS5A inhibitor-resistant hepatitis C virus in patients who failed daclatasvir and asunaprevir therapy | Q41248646 | ||
Infrequent development of resistance in genotype 1-6 hepatitis C virus-infected subjects treated with sofosbuvir in phase 2 and 3 clinical trials. | Q41722679 | ||
In vitro antiviral activity and preclinical and clinical resistance profile of miravirsen, a novel anti-hepatitis C virus therapeutic targeting the human factor miR-122. | Q42181792 | ||
P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
P6216 | copyright status | copyrighted | Q50423863 |
P407 | language of work or name | English | Q1860 |
P921 | main subject | Hepatitis C virus | Q708693 |
P304 | page(s) | 30939 | |
P577 | publication date | 2016-08-03 | |
P1433 | published in | Scientific Reports | Q2261792 |
P1476 | title | Efficient Suppression of Hepatitis C Virus Replication by Combination Treatment with miR-122 Antagonism and Direct-acting Antivirals in Cell Culture Systems | |
P478 | volume | 6 |
Q59350656 | Depletion of MicroRNA-373 Represses the Replication of Hepatitis C Virus via Activation of Type 1 Interferon Response by Targeting IRF5 |
Q89043628 | Differentiation in stem/progenitor cells along fetal or adult hepatic stages requires transcriptional regulators independently of oscillations in microRNA expression |
Q55280981 | Host-targeting therapies for hepatitis C virus infection: current developments and future applications. |
Q38289423 | Safety, tolerability, and antiviral effect of RG-101 in patients with chronic hepatitis C: a phase 1B, double-blind, randomised controlled trial |
Q52584714 | Unexpected Replication Boost by Simeprevir for Simeprevir-resistant Variants in Genotype 1a Hepatitis C Virus. |
Search more.